Global Trial in APG2575 for Patients With CLL/SLL

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Trial Details

NCT ID
NCT06104566
Phase
PHASE3
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • lisaftoclax +BTK inhibitor
  • BTK inhibitor
Locations (sample)
  • Tuscon, Arizona, United States
  • Anaheim, California, United States|33.83529,-117.9145
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • Peoria, Illinois, United States|40.69365,-89.58899

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BT…
  • ECOG Performance Status grade 0-2
  • Adequate bone marrow function independent of growth factor or transfusion support within 2 weeks of screening initiation as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →